A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

USA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a ...

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment - ...